Search | Clinical Trials Finder

Conditions: Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage IIIA, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
Interventions: TheraBionic P1 Device; Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 22 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Clarkston, Michigan • Detroit, Michigan • Farmington Hills, Michigan + 5 more

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Breast Carcinoma
Interventions: Counseling, Educational Intervention, Questionnaire; Other · Behavioral
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer, Cancer Survivor, Psychosocial Effects of Cancer and Its Treatment
Interventions: telephone-based intervention, counseling intervention, educational intervention, questionnaire administration, psychosocial assessment and care, quality-of-life assessment; Behavioral · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cancer Survivor, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: One-on-one interview, Survey Questions; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: anastrozole, simvastatin, pharmacological study, adjuvant therapy; Drug · Other · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Hot Flashes
Interventions: informational intervention; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, medical chart review, questionnaire administration; Genetic · Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cognitive/Functional Effects, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: ultrasound imaging, questionnaire administration, assessment of therapy complications, quality-of-life assessment, magnetic resonance imaging; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIA Breast Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Breast Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Breast Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Breast Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine; Drug · Other · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: Pazopanib Hydrochloride, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Pharmacological Study, Laboratory Biomarker Analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: nicotine, Usual Care; Drug · Behavioral
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 19 Years to 120 Years
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1990
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 59 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2023
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer, Fatigue, Sleep Disorders
Interventions: Tamoxifen, triptorelin, Exemestane; Drug
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 13
States / cities: Sacramento, California • Fort Collins, Colorado • Norwalk, Connecticut + 7 more

Conditions: Breast Cancer, Fatigue, Hypothyroidism
Interventions: physiologic testing, fatigue assessment and management, management of therapy complications; Other · Procedure
Lead sponsor: University of South Florida; Other
Eligibility: 20 Years to 80 Years · Female only
Enrollment: 541 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 41
States / cities: Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Breast Biopsy Procedure, Carboplatin, Cyclophosphamide, Darolutamide, Doxorubicin, Epirubicin, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Surgical Procedure, Ultrasound Imaging; Procedure · Drug · Biological
Lead sponsor: Vandana Abramson; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: celecoxib, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Control Intervention; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: adjuvant therapy, conventional surgery, intraoperative radiation therapy; Procedure · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cancer Survivor, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Educational Intervention; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer
Interventions: Filgrastim, Docetaxel, Doxorubicin, Surgery; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer, Musculoskeletal Complications, Pain
Interventions: duloxetine hydrochloride, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 714
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more

Conditions: Breast Cancer
Interventions: Placebo, Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 93
States / cities: Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 81 more

Conditions: Breast Cancer, Depression, Weight Changes
Interventions: Calcium-Rich Diet, Arm 2: Exercise + Calcium-Rich Diet, Exercise + Fruit & Vegetable, Low Fat + Calcium Diet; Dietary Supplement · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 4
States / cities: Durham, North Carolina • Goldsboro, North Carolina • Winston-Salem, North Carolina + 1 more

Conditions: HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim; Other · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Seattle, Washington • Madison, Wisconsin

Search by objective public record fields.

A Study of the TheraBionic P1 Device in Breast Cancer

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study

Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors

Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity

Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer

Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial

Biomarkers in Blood Samples From Older Breast Cancer Survivors

Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer

Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors

Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer

Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors

Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Survival TRaining for ENhancing Total Health (STRENGTH)

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission